Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 108   

Articles published

NVS 84.67 +0.26 (0.31%)
price chart
Novartis Gets Breakthrough Status For Oncology Drug
Novartis AG (ADR) (NVS) announced on March 26 that the US Food and Drug Administration (FDA) has granted its investigational compound, certinib (LDK378), a �breakthrough therapy� status.
Related articles »  
Pfizer, AstraZeneca, and Novartis Reveal New Business Developments
With small cap biotech companies flooding the news, Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN), and Novartis AG (ADR) (NVS) revealed developments in their businesses. Here is a roundup of what happened in the news for these three pharmaceutical ...
Related articles »  
Biotech Stocks With Exciting Development Projects
biotechnology Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar positively glows with important milestones that could ignite portfolios.
Related articles »  
Traders Recap - Seattle Genetics, Inc (NASDAQ:SGEN), Novartis AG (ADR ...
Las Vegas, NV - April 14, 2014 - (Tech Sonian) - Seattle Genetics, Inc (NASDAQ:SGEN) recently declared that it will receive milestone payments from Takeda Pharmaceutical Company Limited (Takeda) totaling $6 million as a result of achieving the first ...
Novartis' Lead Ceritinib Could Capture Market Share From Pfizer
A 21 Center Phase I Clinical Trial of Ceritinib (LDK378), Novartis A.G. (NVS), published its findings of patients with advanced non-small-cell lung cancer (NSCLC) in the New England Journal of Medicine on March 27, 2014.
Related articles »  
Novartis AG (ADR) (NVS) news: FDA oks Novartis, Roche treatment for hives
The FDA has approved Novartis' (NVS) and Roche's (RHHBY) Xolair treatment for Chronic Idiopathic Urticaria (CIU), a form of hives.
Related articles »  
Novartis reshuffles Japanese management following scandals
The reshuffle comes after Novartis said yesterday that staff hid severe side effects that some patients suffered in a trial for a leukemia drug.
Related articles »  
ADR Shares End Higher; ING, Novartis Shares Active
... the Asian index climbed 1% to 142.53, the Latin American index added 0.8% to 278.23 and the emerging-markets index rose 0.7% to 273.12.
Mix Stock In Focus: Actavis (NYSE:ACT), Novartis (NYSE:NVS), Total (NYSE:TOT)  eMarketsDaily
Related articles »  
Investor's Alert �Novartis AG (ADR) (NYSE:NVS), GlaxoSmithKline plc (ADR ...
Novartis AG (ADR) (NYSE:NVS) ended lower -1.08% and complete the day at $82.51. The total number of shares changed hands during the day was 1.57 million.
Investor's Alert: Novartis (NYSE:NVS), AstraZeneca (NYSE:AZN), Global ...  Gaining Green
Related articles »  
Drug Manufacturers Has Concerns- Pfizer Inc. (NYSE:PFE), Novartis AG (ADR ...
Pfizer Inc. (PFE) reported that its Xalkori cancer drug give better results to chemotherapy as a first-line treatment for a certain type of advanced non-squamous non-small cell lung cancer in a current Phase III study.
Related articles »